News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SciClone Pharmaceuticals, Inc.'s (SCLN) European Partner Sigma-Tau Pharmaceuticals Initiates Phase 3 ZADAXIN Hepatitis C Triple Therapy Trial; First Patients Enrolled And Receiving Treatment


10/19/2005 5:08:49 PM

SAN MATEO, Calif.--(BUSINESS WIRE)--Dec. 23, 2004--SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that Sigma-Tau, its European development and marketing partner for ZADAXIN(R), has begun enrolling patients infected with the hepatitis C virus (HCV) in a multi-center European phase 3 clinical trial evaluating the triple therapy combination of ZADAXIN, pegylated interferon alpha and ribavirin. Currently, Sigma-Tau estimates completing enrollment of the 550-patient trial by the end of 2005 and results may be reported by the end of 2007.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES